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The aim of this paper was to assess the nonsurgical treatment of oral leukoplakia (OL). A medline search from 1983 to 2009
was conducted. The topical or systemic nonsurgical treatments or combination of both was reviewed. The primary outcomes
of interest were clinical resolution, malignant transformation, follow-up, and recurrence of OL. Studies showed a rate higher
than 50% of clinical resolution with photodynamic therapy, beta-carotene, lycopene, or vitamin A. Few studies reported rates
of recurrence from 5 to 67% and of malignant transformation from 8 to 23%. There is a lack of randomized clinical trials that
assess the eﬀectiveness of nonsurgical treatment of OL. At this time, randomized controlled trials for nonsurgical treatment of
OL demonstrate no evidence of eﬀective treatment in preventing malignant transformation and recurrence. It reinforces that even
after clinical resolution, OL should be regularly followed.
1.Introduction
Oral leukoplakia (OL) is a premalignant lesion described
as “a predominant white lesion of the oral mucosa which
cannot be deﬁned as any other known lesion” [1]. According
to Warnakulasuriya et al. [2], the new concept of OL shall
acknowledge white lesions with questionable risk of being
an OL, being excluded any other pathologies or known
disorders which do not present potential malignant risk such
as candidiasis, lupus erythematosus, lichen planus, hairy
leukoplakia, frictional keratosis, nicotinic stomatitis, and
leukoedema [3, 4].
OL’s etiopathogenesis encompasses two broad categories,
as follows: OL of unknown etiology or idiophatic and OL
associated with tobacco use [3]. OL is more often found
among older and elderly men, and its prevalence increases
with age advancement. It has been estimated that less than
1% of the aﬀected men are younger than 30 years old and
that the prevalence increases to 8% in male patients older
than 70 years old and to 2% in female patients of 70 years or
more.OL’shistopathologicaspectsmayvaryfromepithelium
atrophy to hyperplasia, which can be associated with varying
degrees of epithelial dysplasia [4, 5].
OL located on the ﬂoor of the mouth, soft palate, and
tongue are considered as high-risk lesions, while, in other
areas, they may be considered as of low malignancy risk
[5, 6]. OL has an annual malignant transformation rate of
0.1%to17%[7–10].Somefactorsmaycontributetoincrease
thechanceoftheOLbecomingmalignant[4,6,11,12];these
include the following.
(1) Gender: female patients tend to present a higher risk
of developing the malignant form [11, 12].
(2) A long-time OL lesion: OL resistant to the treatments
and what persist for long time may have worse
prognosis than recent [12].
(3) OL in sites of high risk: lesions in the ﬂoor of mouth,
ventrolateral tongue and soft palate have a high risk
of malignant transformation [6, 12].2 International Journal of Dentistry
(4) OL among nonsmokers (idiopathic): nonsmokers
with OL have an increased rate of malignant trans-
formation in relation to OL in smokers [11, 12].
(5) Nonhomogenous OL-type: nonhomogenous OL
lesions have a mixed color of white and red alter-
ations, and an exophytic, papillary, or verrucous
aspect; regardless of treatment, they exhibit a high
recurrence rate and often eventually transformation
to squamous cell carcinoma [4, 12].
(6) Epithelial dysplasia: OL with moderate and severe
dysplastic lesions had a signiﬁcantly higher risk of
developing a squamous cell carcinoma than OL
without epithelial dysplasia or with mild epithelial
dysplasia [7, 9, 12].
In order to conduct treatment for OL, the degree of
epithelial dysplasia may be assessed. In the presence of
moderate or severe epithelial dysplasia, surgical treatment is
recommended [9]. However, OL presenting low to moderate
malignantriskmaybeeithercompletelyremovedornot,and
the decision should consider other factors such as location,
size and, in the case of smokers, the patient’s engagement
in smoking cessation [4, 9, 13]. OL surgical treatment may
be performed either through conventional surgery [4, 5, 14],
electrocauterization, laser ablation [15, 16], or cryosurgery
[17, 18]. Recurrence of OL after surgical treatment has been
reported in 10%–35% of cases [19–22].
Nonsurgical treatment may also be considered for the
management of OL [17, 18, 23]. This modality oﬀers min-
imal adverse eﬀects to patients, especially for patients with
widespread OL that involves a large area of the oral mucosa
or patients with medical problems and, consequently, high
surgical risks [24]. Additionally, potential advantages of the
nonsurgical treatment of OL include easy application that
does not require treatment at a medical center and relative
low cost [25].
The purpose of this paper is to present the current
nonsurgical treatment options for OL. A Medline from 1983
to 2009 search was conducted using the following key-
words: nonsurgical treatments of OL, retinoids, carotenoids,
lycopene, photodynamic therapy. We included 21 studies
of patients with diagnosis of OL. The primary outcomes
of interest were clinical resolution, follow-up, and when
reported, malignant transformation and recurrence. The
topicalorsystemicnonsurgicaltreatmentsorcombinationof
bothwerereviewed.Furthermore,themechanismsofaction,
biodisponibility, toxicity, and side eﬀects of these treatments
were analyzed. Table 1 presents the nonsurgical treatment
options for OL.
2. Carotenoids
2.1.Beta-Carotene. Thecarotenoidsareagroupofextremely
hydrophobic molecules with little or no solubility in water
[26]. Beta-carotene is a carotenoid commonly found in
dark green, orange or yellowish vegetables, such as spinach,
carrots,sweetpotato,mango,papaya,andoranges[27].Beta-
carotene is a vitamin A precursor [26, 28–30]. The only
known eﬀect of excessive beta-carotene intake is a state in
which the skin becomes strongly yellowish, the so-called
carotenodermy, which disappears in a few weeks after the
reduction of consumption [26]. While some authors have
demonstrated the absence of side eﬀects in patients that have
received beta-carotene treatment [27], in other studies, the
supplement diet based on beta-carotene caused headaches
and muscle pain in some of the patients [31].
Theuseofbeta-carotenehasbeenrecommendedinorder
to prevent OL and possibly oral cancer [31]. The potential
beneﬁts and protective eﬀects against cancer are possibly
related to its antioxidizing action [32–34]. This function
is accomplished through a ligation between beta-carotene
and oxygen, which is an unstable reactive molecule, thus
diminishing the damaging eﬀects of free radicals [34, 35].
AccordingtoLiedeetal.[32],adietsupplementedwithbeta-
carotene can prevent changes in the oral mucosa, especially
in smoker patients, who present low serum levels of vitamin
C and beta-carotene when compared to nonsmokers. It has
also been shown that beta-carotene has a better therapeutic
clinic response in the prevention of OL lesions in smoker
patients than in the nonsmoker ones [36]. Results from
Sankaranarayanan et al. [31] demonstrated that one third of
patients (15 out of 46) that used 360mg beta-carotene per
week during 12 months presented a complete resolution of
OL. In the evaluative sessions one year after the treatment, 8
out of 15 (54%) of the patients who had a complete response
presented recurrence. Moreover, 12 months after stopping
the supplements, 5% (2 out of 15) of the patients who had
made use of beta-carotene developed malignant neoplasia
adjacent to the OL. Side eﬀects were observed in 5 patients,
being 3 with headaches and 2 developed muscular pain.
In another study, 23 patients with OL were treated with
beta-carotene, in oral doses of 90mg/day, for three cycles of
3 months each. Of 18 patients who completed the study, 6
(33.3%) showed complete clinical response. No signiﬁcant
clinical signs of toxicity were detected in any of the patients
[37].
Twenty-four patients with OL were employed in another
study with beta-carotene employed at a dose of 30mg/day
for six months. Only 2 patients (8.3%) presented a complete
clinical response and 15 patients (62.5%) had partial clinical
response [38]. Garewal et al. [39] evaluated 50 patients with
OL, treated with beta-carotene at a dose of 60mg/day, for
six months. Only 2 patients (4%) demonstrated a complete
clinicalresponse.Relapseswerefoundin4patients.Asecond
biopsy was obtained after 6 months of therapy in 23 patients.
There was no change in the degree of dysplasia in 14, with
improvement of at least 1 grade in 9 (39%).
In the revised studies, the percentage of patients with
clinical resolution ranged from 4% to 54%, with dosages
regimes from 20 to 90mg/day of beta-carotene in time
periods from 3 to 12 months (Table 1).
2.2. Lycopene. Lycopene is a carotenoid without provitamin
A action. This is a fat-soluble red pigment found in
some fruit and vegetables. The greatest known source of
licopene is tomatoes, which are widely employed in cooking
[40]. There is a positive relationship between lycopeneInternational Journal of Dentistry 3
Table 1: Nonsurgical treatments options for oral leukoplakia.
Author Therapy Dose Number of
patients
Clinical
resolution (%)
Follow-up
(months) Recurrence
Malignant
transformation
(%)
Benner et al. [66] Systemic Alfa
tocoferol 400IU 43 20% 24 NR NR
Garewal et al. [38] Systemic
Beta-carotene 30mg/day 24 8% 6 NR 8%
Toma et al. [37] Systemic
Beta-carotene 90mg/day 23 26% 7 5% NR
Sankaranarayanan
et al. [31]
Systemic
Beta-carotene 360mg 46 54% 12 5% NR
Liede et al. [32] Systemic
Beta-carotene 20mg/day 24 NR 60–84 NR NR
Garewal et al. [39] Systemic
Beta-carotene 60mg/day 50 4% 18 17% 8%
Sankaranarayanan
et al. [31]
Systemic
Isotretinoin 300.000IU 42 52% 12 67% NR
Stich et al. [74] Systemic
Vitamin A
200.000–
300.000IU 21 57% 12 NR NR
Nagao et al. [47] Systemic
Lycopene NR 48 NR NR NR NR
Singh et al. [48] Systemic
Lycopene 4–8mg 58 25-55% 3 NR NR
Hammersley et al.
[24]
Topical
Bleomycin 0,5% 8 NR 12 NR NR
Epstein et al. [25] Topical
Bleomycin 1% 19 32% 40 NR 11%
Shah et al. [73] Topical
Vitamin A 1–5mg 11 27% 11 18% NR
Epstein and Gorsky
[78]
Topical
Tretinoin 0,05% gel 26 27% 42 40% NR
Piattelli et al. [72] Topical
Isotretinoin 1% 10 10% 48 NR NR
Lippman et al. [88] Systemic 4 HPR 200mg/day 35 0 9 NR 23%
Tradati et al. [87] Topical 4 HPR NR 8 25% NR NR NR
K¨ ubler et al. (1998) Topical PDT ALA 20% 20 25% 3 NR NR
Si´ eron et al. [90] Topical PDT ALA 10% 5 80% 6 20% NR
Siero´ ne ta l .[ 96] Topical PDT ALA 10% 12 83% 6 8% NR
Chen et al. [97] Systemic PDT ALA 24 33% NR NR NR
IU: International Unit; NR: not reported; 4 HPR: Fenretinide; PDT: Photodynamic therapy; ALA: Aminolevulenic acid.
consumption and a reduction in the risk of the development
of degenerative diseases caused by free radicals, such as
cancer and cardiovascular diseases [41, 42]. Lycopene has the
uncommon feature of becoming bound to chemical species
that react to oxygen, thus being the most eﬃcient biological
antioxidizingagent[41].Duethisproperty ,studieshavebeen
enthusiastically conducted with lycopene, in order to ﬁnd
out whether or not it could be an alternative to protect
patients against the damaging eﬀects of free radicals [41].
In addition to its antioxidizing property, lycopene also has
the capacity to modify intercellular exchange junctions, and
this is considered to be an anticancer mechanism [41]. In
vitroexperimentshaveshowntheinhibitionoftheprocessof
humanneoplasticcellulargrowthbylycopene,sincethispro-
tein interferes in growth factor receptor signaling and, thus,
in cellular cycle progression, as previously demonstrated for
neoplastic cells from the prostate gland [43].
Consumed carotenoids are incorporated in lipidic
micelles and are absorbed by enteric mucosa through passive
diﬀusion and distributed to the organs by the plasmatic
lipoproteins. Lycopene release from the food matrix, pres-
ence of fat in the diet, and heat-induced isomerization from
trans to cis mode are some factors inﬂuencing lycopene
absortion and biodisponibility [44].
Lycopene is better absorbed in oil resin capsules and
in tomato juice than in the form of raw tomatoes [45].4 International Journal of Dentistry
Hoppeetal.[46]determinedthebiodisponibilityofonesyn-
thetic type of lycopene, in contrast with the performance of
a lycopene oil resin extracted from tomatoes, and concluded
that both sources of lycopene have the same bioavailability.
Nagao et al. [47] evaluated 48 patients with OL (38 men
and 10 women) and 192 control patients to verify the
relationship between OL with serum levels of retinol, alpha-
tocopherol, zeaxantine and luteine, cryptoxantine, lycopene,
and alpha and beta-carotenes. The serum levels of lycopene
and beta-carotene, among the 38 men suﬀering from OL,
were signiﬁcantly lower than those of the control group (P<
.005). Authors suggested that improvement of micronutrient
levels of beta-carotene and lycopene in Japanese males with
a high frequency of smoking habit may protect against the
relative risk of OL in this population.
Singh et al. [48] assessed the eﬃciency of lycopene in 58
cases of OL. The patients were divided into three groups,
a n dr e c e i v e d8m g / d a y ,4m g / d a y ,a n dp l a c e b of o rap e r i o do f
three months. The supplementation of lycopene (8mg/day
and 4mg/day) reduced hyperkeratosis (clinically measured
by the size of the lesion) with a similar eﬃciency in 80% of
thecases.Thecompleteclinicalresponseofpatientsreceiving
8mg/daywas55%and4mg/daywas25%,butthisdiﬀerence
was not statistically signiﬁcant.
No systemic signiﬁcant toxical eﬀect of lycopene has
been observed and there is no evidence of side eﬀects
from the treatment with lycopene [49]. Lycopene is a
promising candidate in reducing cancer and chronic diseases
in human beings; however, further research is needed to
clarify its potential function in human health, according to
the following criteria [50, 51].
(1) Factorsinﬂuencingtheuptakeoflycopeneinthediet,
including the way it interacts with other carotenoids.
(2) Human metabolism and the possible function of the
metabolites and cis-trans isomers.
(3) Mechanisms of the direct or indirect modulation of
cancer.
(4) Studies based on evidences of treatment in human
beings.
(5) Mechanisms of lycopene deposition in human tis-
sues.
(6) Lycopene eﬀects in the immunological system.
Only one study evaluated lycopene in clinical resolution
of OL. The time period was three months, the dosages
regimes from 4mg/day and 8mg/day and patients had
clinical resolution 25 and 55%, respectively (Table 1).
3.Vitamins
3.1. L-Ascorbic Acid (Vitamin C). L-ascorbic acid (L-AA),
the so-called vitamin C, is found in citrous fruits such as
kiwi, strawberries, papaya, and mango [52]. The current
US recommended daily allowance for ascorbic acid ranges
between 100–120mg/per day for adults [52]. It has been
suggestedthatadailyintakeofatleast140mg/dayisrequired
for smokers because they usually present a reduction of the
L-AA concentration in serum leukocytes [53].
L-AA has antioxidizing properties and reacts with super-
oxide produced as a result of the cells’ normal metabolic pro-
cesses; this inactivation of superoxide inhibits the formation
of nitrosamines during protein digestion and helps avoid
damage to DNA and cellular proteins [54]. L-AA toxicity
does not occur, since vitamin is water-soluble and a decrease
in absorption eﬃciency occurs when consumption exceeds
180mg/day [55].
The ability of L-AA to maintain oral mucosa integrity
is very little documented. One study examined the presence
of oral mucosal lesions in subjects with low L-AA levels
in plasma, compared to controls. Subjects with low plasma
L-AA levels ≤25μmol/l) (n = 106) formed the study
group and individuals with normal L-AA levels (≥50μmol/l)
(n = 103) formed the control group. Oral mucosal lesions
in all subjects were deﬁned clinically as petechias, OL,
and lichenoid lesions. There was a statistically signiﬁcant
diﬀerence between the groups only for OL, where the
prevalence of OL was higher when smoking was combined
with L-AA deﬁciency [56].
In another study [57], 24 OL patients were treated with
an association of beta-carotene, vitamin E, and L-AA, and
an increase was observed in the reversion of oral mucosa
dysplasia. In 97.5% of patients, dysplasias were diminshed
by use of antioxidant combinations. The reversion of the
oral mucosa dysplastic changes was more evident in the
patients using antioxidative vitamins that stopped smoking
and ingestion of alcohol.
There are no studies regarding the eﬃcacy of the use of
L-AA alone for OL treatment.
3.2. α-Tocoferol (Vitamin E). α-Tocoferol (AT) is the com-
monest and most active form of vitamin E. It is found
in plant oil, margarine, and green leaves [58–61]. The
recommended daily limit rates are 10mg/day for adult men
and 8mg/day for adult women [62]. Its absorption rate
i sr e d u c e dw h e nc o n s u m p t i o ne x c e e d s3 0 m g / d a y[ 63]. α-
Tocoferol is an eﬀective antioxidant at high levels of oxygen,
protectingcellularmembranesfromlipidicperoxidation[59,
60, 64, 65]. Erhardt et al. [35] showed that supplementation
with AT led to a signiﬁcant rise in the concentration of this
antioxidant in the plasma. In contrast, supplementation did
not lead to a signiﬁcant increase in the concentration of AT
in cells of the oral mucous membrane.
Benner et al. [66] evaluated the toxicity and eﬃcacy of
AT in 43 patients with OL in use of 400IU twice daily
for 24 weeks. Follow-up was performed at 6, 12, and 24
weeks after the beginning of treatment to assess toxicity,
clinical response, and serum AT levels. It was observed that
10 patients (23%) had complete clinical remission of lesion
and 10 (23%) had a partial clinical response. Nine (21%)
had histologic responses (complete reversal of dysplasia to
normal epithelium). Mean serum AT levels were 16.1μg/mL
at baseline and increased to 34.29μg/mL after 24 weeks of
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Seventy-nine patients with OL were enrolled in an
antioxidant supplementation program that consisted of
30mg of beta-carotene, 1000mg of L-AA, and 800IU of AT
per day, which were taken for 9 months. No side eﬀects were
noticed during the course of the study. Although no patients
showed complete resolution of the OL, 55.7% showed
reduction in the size of the OL after 9 months. Clinical
improvement was observed in 90% of the patients who had
reduced risk factors, compared with 48.8% of improvement
in those who did not. Squamous cell carcinoma developed
in seven patients (8.9%) within the preexisting OL during or
shortly after completion of the study [33].
Some studies evaluated the administration of AT, alone
or combined, used the dosage of 800IU/day from 6 to 9
months (Table 1).
3.3. Retinoic Acid (Vitamin A). The current deﬁnition of
retinoid includes all the natural and synthetic compounds
withanactivitysimilartothatofVitaminA.VitaminAexists
in the human body as various interconvertible compounds,
notably retinal (essential for vision) and retinol, which is
the most potent analogue and the main form of storage
and transportation [27, 67]. Retinoic acid is obtained from
carotene and animal products such as meat, milk, and eggs,
which, while in the intestine, are converted, respectively,
into retinal and retinol [27, 67]. The absorption of retinoids
increases by up to 50% when ingested with food. Retinoids
are transported in the blood by plasmatic proteins. Hepatic
metabolization is achieved via the action of cytochrome P-
450 [27, 67]. Hypervitaminosis occurs when consumption
exceeds the liver’s capacity to store retinoids [30].
Topic retinoids were initially tested against diseases
related to keratinization. 13-cRA was used for the ﬁrst time
against acne, in 1969. The so-called “retinoic dermatitis”
is the main side eﬀect of tretinoin, this leads to cuta-
neous irritation characterized by erythema, scaling, ardency,
and/or pruritus. “Retinoic dermatitis” occurs frequently, and
patients ought to be previously instructed with regard to its
occurrence. Furthermore, patients should also be warned to
avoid the sunlight and to wear sunscreen [68].
The use of systemic retinoids is not indicated in cases
of (1) pregnancy or probability of pregnancy; (2) noncom-
pliance with the use of contraceptives; (3) breast feeding;
(4) hypersensitivity to parabeno (in isotretinoin capsules).
It is, relatively, not indicated in cases of (1) leukopenia; (2)
hypothyroidism (patients using bexarotene); (3) high levels
of cholesterol and triglyceride; (4) hepatic malfunction; (5)
renal malfunction [67, 69]. Absorption of systemic retinoids
is boosted by up to 60% when they are taken together with
the meals.
Supplementation with retinoids for OL treatment began
in the 1960s. However, this treatment was not widely
accepted due to its side eﬀects—hypervitaminosis, toxicity,
teratogeniceﬀects,andalterationsinvariousorganicsystems
[70]. At the cellular-level, retinoids interact with surface
receptors and penetrate the cell. They are subsequently
metabolized and transported to the nucleus by various
proteins. Retinoids aﬀect diverse processes, such as keratin
production, the expression of growth factors and kinases,
oncogenesis, apoptosis, production of the collagen matrix,
immunologic and inﬂammatory response, cellular diﬀer-
entiation, embrionary morphogenesis and carcinogenesis
[26, 30].
13-cRA is the retinoid recommended for OL treatment.
Theuseof13-cRAhasbeenshowntobeeﬀectiveinresolving
OL [33, 34]. However, the high recurrence rates after short
periods of discontinuance, together with its side eﬀects, are
limiting factors [33, 34, 70] .V a r i o u ss t u d i e sh a v ee v a l u a t e d
the therapeutic eﬀectiveness of vitamin A derivatives in
the treatment of OL, although not all studies have shown
concordant results (Table 1). In one study, of the 45 patients
registered, 7 (15.5%) had OL. Patients received a ﬁxed dose
of 13-cRA (10mg/day) plus an escalating dose (beginning
at 800IU/day, until 2000IU/day) for 4 months. Seventy-
one percent of OL patients had complete clinical responses
[71]. A study conducted with retinoic supplementation
(300.000IU retinol acetate) for OL treatment demonstrated
complete resolution in 52% of patients. Side eﬀects observed
included six patients with headaches, ﬁve patients reported
muscle pain, and two patients reported dry mouth [31].
Kaugars et al. [34] implemented retinoic supplementa-
tion in various dosages for OL treatment. Fifty percent of
patientshadcompleteorpartialclinicalresolutionofOL,but
with side eﬀects such as dizziness and headache. Moreover,
for most of the patients with clinical resolution of the lesion,
OL recurred upon the discontinuance of medication. Some
patients ceased treatment due to its side-eﬀects. On the
other hand, during the assessment of 13-cRA topical use
(0.1% isotretinoin gel) for 4 months, in 9 patients with OL,
20% showed complete clinical response to treatment and no
patient reported adverse eﬀects [72].
In another study, 13-cRA was used in 16 patients with
OL for six months. Three patients were entered at a dosage
of 3mg/day, eight at 5mg/day, and ﬁve at 10mg/day.
Eleven patients completed the study: 3 had complete clinical
responses(2at10mg/dayand1at5mg/day).Recurrencewas
observed in two of these three patients [73].
During another study, patients with OL were distributed
into two groups: one receiving 200.000IU vitamin A per
week (n = 21) and the other receiving placebo capsules (n =
33)forsixmonths.Completeremissionwasobservedin57%
of patients that received vitamin A. The administered doses
of vitamin A did not produce any detectable adverse eﬀects
during the trial period. In the placebo group, 7 patients
(21%) formed new OL; whereas no new OL developed in the
vitamin A group over the 6 months [74]. In an additional
study from these same authors, patients with OL were
divided into three groups receiving: group 1, beta-carotene
(180mg/week); group 2, beta-carotene (180mg/week) plus
vitamin A (100.000IU/week), and group 3 placebo, for 6
months. Remission of OL in group 1 (14.8%) and group
2 (27.5%) diﬀered signiﬁcantly from that seen in group 3
(3%). During the trial period, all patients continued to chew
tobacco-containing betel quids [75].
In a study by Toma et al. [76], sixteen patients with
OL were treated with oral 13-cis-retinoic acid. The initial
dose, given for 3 months, was 0.2mg/kg/day, increasing by6 International Journal of Dentistry
a further 0.2mg/kg/day in successive 3 month cycles. The
maximum dosage reached 1.0mg/kg/day. Fourteen of the
patients completed the trial and there was one complete
response obtained at 0.4mg/kg/day. After the retinoic acid
treatment was stopped, patients were followed-up for 12
months; 2 patients showed regression of the responses
obtained after 6 and 9 months [76].
One study, in two phases, was made in 70 patients with
OL. In the ﬁrst phase, the 67 patients were treated at a high
dose of isotretinoin (1.5mg/kg/day) for three months. Fifty-
ﬁve percent of patients demonstrated complete or partial
clinical responses. In the second phase of the study, 59
patients, with responses or stable lesions, were randomly
assigned to maintenance therapy with either beta-carotene
(30mg/day; n = 33) or a low dose of isotretinoin
(0.5mg/kg/day; n = 26) for nine months. Twenty-two
patients (92%) with isotretinoin and 13 patients (45%) with
beta-carotene demonstrated a positive response [77].
Studies focusing on topical vitamin A and their derivates
in the management of patients with OL have been reviewed
by Gorsky and Epstein [23]. The use of topical tretinoin
at 0.05% was evaluated in 26 patients with OL. Patients
were followed for a mean of 23 months. Ten patients
who had partial or no clinical response were submited at
biopsies pre- and posttreatment, and the mean grade of
histological features did not change. Twenty-seven percent
of the patients had a complete clinical remission. Recurrence
of OL was observed in approximately 40% of these patients
after cessation of the applications. The use of topical
vitamin A acid showed a limited eﬀect in controlling OL
[78].
Inanopentrial,theclinicaleﬃcacyoftopicalcalcipotriol
(vitamin D3 analogue) was compared with tretinoin in the
therapy of hyperkeratotic oral lesions (leukoplakia). Forty
patients had histologically proven OL, 20 were treated with
calcipotriol (50mg/g), and the other 20 with tretinoin cream
(0.05%). The treatment was given for 5 weeks and follow-
up was at 4 months, with clinical assessments at 2, 4,
and 5 weeks. Results showed complete resolution of OL in
16 patients in both calcipotriol and tretinoin groups. No
documented topical or systemic adverse reactions and results
were maintained at 4 months [79].
In a 10-year study that followed OL patients, Scardina et
al.[80]assessedtheeﬀectivenessoftopicaluseofisotretinoin
at 0.18%, as compared with 0.05%. Concentrations of
0.18% and 0.05% were given to two diﬀerent groups and
administered twice a day during 3 months. The clinical
resolution was 85% in the 0.18% group, without any adverse
topic or systemic reaction. In addition, epithelial dysplasia
disappeared and there was a signiﬁcant reduction in the size
of the lesion.
In the systemic use with dosage of 300.000IU of retinoic
acid (Vitamin A), a clinical resolution of the 50% has been
demonstrated. In topical use with dosage range from 0.05%
to 1% a clinical resolution from 10% to 27% has been
obtained (Table 1).
3.4. Fenretinide. Fenretinide (4-HPR) or N-(4-hydr-
oxyphenyl) retinamide is a vitamin A analogue that was
synthesized in the United States during the late 1960s. This
retinoid shows a preferential accumulation in breast instead
of liver [81], is eﬀective in the inhibition of chemically
induced mammary carcinoma in rats [82], and has proven
to be less toxic than many other vitamin A analogues
[82, 83]. A characteristic feature of 4-HPR is its ability
to inhibit cell growth through the induction of apoptosis
with mechanisms that may be both receptor-dependent
and receptor-independent. Chemopreventive eﬃcacy of
fenretinide has been investigated in clinical trials targeted
at diﬀerent organs [84–86]. Eight patients with diﬀuse
(nonoperable) oral lichen or OL were treated with 4-HPR
applied topically twice daily. After one month of therapy,
two patients had complete remission and the other six had a
greater than 75% response. 4-HPR was well tolerated, and
no local or distant side eﬀects were observed [87].
A phase II trial of 4-HPR (200mg/day) was carried out
for 3 months in OL patients who had not responded (“de
novo” resistance) or who had responded and then relapsed
(acquired resistance) to the previous treatment with natural
retinoids. Of 35 patients with retinoid-resistant OL, no
patient had complete responses and 12 (34.3%) had partial
responses to 4-HPR. Nine patients had clinical responses
within 9 months of stopping 4-HPR. Toxicity was minimal
and compliance was excellent [88].
Systemic use of 4-HPR with 200mg/day for 3 months in
35 patients demonstrated partial clinical resolution of OL of
12 patients (Table 1).
4.Bleomycin
Bleomycin, a cytotoxic antibiotic, was ﬁrst used for the treat-
ment of neoplasms of the penis and scrotum, but has also
been employed for squamous cell carcinoma of the head and
neckregion,oesophagus,andskin[89].Themostcommonly
adverse eﬀects are mucocutaneous reactions, which include
stomatitis, alopecia, pruritic erythema, and vesiculation of
the skin [27]. Eight patients with OL were treated by the
daily application of a 0.5% (w/v) solution of bleomycin
sulphate in dimethyl sulphoxide (DMSO). After 12 to 15
applications, the white patch peeled oﬀ and the resultant
raw suface was epithelialized over the following 14 days.
Repeatedbiopsiesshowedasigniﬁcantreductionofdysplasia
and keratinisation [27]. The use of topical 1% bleomycin
in DMSO was evaluated for the treatment of dysplastic OL.
Bleomycin was applied once daily for 14 consecutive days to
lesions of the oral mucosa in 19 patients. It was well tolerated
with minor mucosal reactions. Immediate posttreatment
biopsies showed that 75% of patients had resolution of
dysplasia.Ninety-fourpercentofthepatientsattainedatleast
partial clinical resolution. After a mean follow-up period of
3.4 years, 31.6% of patients had no clinically visible lesions.
In 2 patients (11%), malignant transformation occurred
[28].
Topical bleomycin in treatment of OL was used in do-
s a g e so f0 . 5 % / d a yf o r1 2t o1 5d a y so r1 % / d a yf o r1 4d a y s
(Table 1).International Journal of Dentistry 7
5. Photodynamic Therapy
Photodynamic therapy (PDT) is a noninvasive method for
the treatment of premalignant lesions and head and neck
cancers [90, 91]. The principle of PDT is a nonthermal pho-
tochemical reaction, which requires the simultaneous pres-
ence of a photosensitising drug (photosensitiser), oxygen,
and visible light. After a period to allow the photosensitiser
to collect in the target tissue, the photosensitiser is activated
by exposure to low-power visible light of a drug-speciﬁc
wavelength. Mainly, the light source consists of a portable
diode laser and the light is transmitted via laser ﬁbres to
or into the tumour. Illumination of the tumour by light
at the activating wavelength results in the destruction of
cells by a nonfree radical oxidative process. These reactive
oxygen species may damage crucial cell components, such as
structural proteins, enzymes, DNA, and phospholipids. PDT
is a cold photochemical reaction, and the photosensitising
agents are of inherently low systemic toxicity. PDT damage
heals mainly by regeneration rather than scarring. Due to
the organ preserving principle of PDT, important structures
are maintained with good functional and cosmetic outcome
[91, 92].
Several photosensitisers have been developed during the
past. Haematoporphyrin and haematoporphyrin derivatives
were the ﬁrst photosensitisers. Four photosensitisers have
been approved so far: (1) photofrin has been approved
in many countries for the treatment of oesophagus cancer
and lung cancer; (2) 5-Aminolaevulinic acid (ALA) was
also approved in several countries for the treatment of
skin cancer; (3) verteporﬁn for the treatment of macular
degeneration (4) foscan is the only photosensitiser that has
been approved for the treatment of advanced squamous cell
carcinoma of the head and neck in Europe in the year 2001
[93].
The ALA is a naturally occurring compound in the
haem biosynthetic pathway, which is metabolised to a pho-
tosensitive product, protoporphyrin IX (PpIX). The major
advantage of ALA when compared to synthetic photosensi-
tisers is the rapid metabolism, which signiﬁcantly reduces
the period of cutaneous photosensitivity [93]. For most
indications in head and neck surgery, the photosensitiser is
administered systemically by intravenous injection. Only for
very superﬁcial skin lesions or premalignant lesions of the
oral mucosa, the ALA can be applied topically. For all other
indications intravenous application is mandatory [93].
Zakrzewska et al. [94]r e p o r t e dt h r e ef o r m so ft r e a t m e n t
of 10 cases of proliferative verrucous leukoplakia; surgery,
carbon dioxide laser; PDT. PDT was administered to 5
patients, in which there was no recurrence in 3, although
a white halo of hyperqueratosis was observed around the
areasubjectedtotreatment.Resultsshowedarecurrencerate,
after treatment, of 100% for surgical excision and 85.7% for
laser vaporization. PDT oﬀered the best prognosis compared
to the other forms of treatment. K¨ ubler et al. [95]t r e a t e d
20 patients with OL using PDT topic 20% ALA, followed
by light jet at 630nm, 100W/cm2 and 100J/cm2. After 3
months, 5 patients completely responded to the treatment
(there were no clinical signs of OL), 4 partially responded
(the lesion was reduced or looked better), 3 did not respond
(no clinical change), and 1 had a partial response being
submitted to treatment again, resulting in the disappearance
of the lesion. No recurrence was observed at 9 months after
this treatment.
Si´ eron et al. [90] treated 5 patients with OL using
topical 10% ALA on the lesion, followed by argon laser
(635nm, 100–250J/cm2). Four of the 5 patients completely
responded. In one case, there was recurrence after 6 months,
however, after 2 additional sessions, the lesions completely
disappeared. This same author [96] observed the therapeutic
response with PDT for OL in twelve patients topically
treated with ALA at 10%, activated by a laser at 635nm
and 100J/cm2 per session, for 6 to 8 sessions. There was
a complete response (total wash out of the leukoplakia in
the visual inspection conﬁrmed by specimen biopsy) in 10
cases (83%). One recurrence was reported after 6 months of
follow-up.
Chen et al. [97] treated 24 patients with OL using
20% ALA-PDT, once a week; another 24 patients used 20%
ALA-PDT twice a week. In the latter group, 8 completely
responded to the treatment, 16 partially responded, and 9
did not. All patients from the twice-a-week group responded
signiﬁcantly better than those treated only once a week.
From the studies using PDT-ALA in topical concentra-
tionsfrom10to20%,itmaybeobservedaclinicalresolution
of OL of the 25% to 80% (Table 1).
6. Conclusion
Several clinical trials have investigated the treatment of OL
with use of supplements. Although the administration of
retinoic acid and beta-carotene has some eﬃcacy to resolve
OL, the studies were based on small samples and short
periods of follow-up. Given the side eﬀects and counter-
indications of antioxidizing agents, with the exception of
lycopene, the use of agents requires careful control. The
small number of patients, the lack of controls, the lack
of widely accepted criteria for classifying OL, the vari-
ability in nonsurgical treatment protocols, and diﬀerences
in histopathologic evaluation diﬃcult the interpretation of
data of the few randomized clinical trials in nonsurgical
treatment of OL. At this time, randomized controlled trials
for nonsurgical treatment of OL demonstrate no evidence of
eﬀective treatment in preventing malignant transformation
and recurrence. It reinforces that after clinical resolution, OL
should be regularly followed.
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